David F. Heigener

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Bonne Biesma, David F. Heigener et al. · Journal of Clinical Oncology · 2012 · 256 citations · Full text

Low-Molecular-Weight Heparin Versus Placebo for the Prevention of Venous Thromboembolism in Metastatic Breast Cancer or Stage III/IV Lung Cancer

Sylvia Haas, Mathias Freund, David F. Heigener et al. · Clinical and Applied Thrombosis/Hemostasis · 2012 · 179 citations

Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study

Martin Reck, Nico van Zandwijk, Cesare Gridelli et al. · Journal of Thoracic Oncology · 2010 · 134 citations · Full text

Oncology, Safety Findings, Medicine +6

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from German Centers in the TRUST Study

Claus-Peter Schneider, David F. Heigener, Kathrin Schott-von-Römer et al. · Journal of Thoracic Oncology · 2008 · 96 citations · Full text

Medicine, Pathology, Bronchial Neoplasm +9

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations Pretreated With Reversible EGFR Inhibitors

David F. Heigener, Christian Schumann, Martin Sebastian et al. · The Oncologist · 2015 · 87 citations · Full text